The Effects Of Atir Blocker On The Severity Of Covid19 In Hypertensive Inpatients And Virulence Of Sarscov2 In Hypertensive Hace2 Transgenic Mice Xiaoliang Jiang Huadong Li Yong Liu Linlin Bao Lingjun Zhan Hong Gao Wei Deng Jing Xue Jiangning Liu Xing Liu Junli Li Jie Wang Shuang Wu Mingzhe Yan Wei Luo Pedro A Jose Chuan Qin Xiuhong Yang Dingyu Zhang Zhiwei by Xiaoliang Jiang & Huadong Li & Yong Liu & Linlin Bao & Lingjun Zhan & Hong Gao & Wei Deng & Jing Xue & Jiangning Liu & Xing Liu & Junli Li & Jie Wang & Shuang Wu & Mingzhe Yan & Wei Luo & Pedro A. Jose & Chuan Qin & Xiuhong Yang & Dingyu Zhang & Zhiwei... instant download after payment.

AbstractAngiotensin-converting enzyme 2 (ACE2) is required for the cellular entry of the severe acute respiratory syndrome coronavirus2. ACE2, via the Ang-(1-7)-Mas-R axis, is part of the antihypertensive and cardioprotective effects of the renin-angiotensinsystem. We studied hospitalized COVID-19 patients with hypertension and hypertensive human(h) ACE2 transgenic mice todetermine the outcome of COVID-19 with or without AT1 receptor (AT1R) blocker treatment. The severity of the illness and thelevels of serum cardiac biomarkers (CK, CK-BM, cTnI), as well as the inflammation markers (IL-1, IL-6, CRP), were lesser inhypertensive COVID-19 patients treated with AT1R blockers than those treated with other antihypertensive drugs. HypertensivehACE2 transgenic mice, pretreated with AT1R blocker, had increased ACE2 expression and SARS-CoV-2 in the kidney andheart, 1 day post-infection. We conclude that those hypertensive patients treated with AT1R blocker may be at higher risk forSARS-CoV-2 infection. However, AT1R blockers had no effect on the severity of the illness but instead may have protectedCOVID-19 patients from heart injury, via the ACE2-angiotensin1-7-Mas receptor axis.Keywords Coronavirus disease 2019 . Hypertension . AT1Abbreviationsreceptor blocker . Angiotensin converting enzyme 2Ang1-7 Angiotensin 1–7Ang Angiotensin